Ian Miscampbell, managing partner at UK-based Sixth Element Capital describes in a television interview how the CRT Pioneer Fund has established with Cancer Research Technology and the European Investment Fund to create a £50m investment fund to bridge the investment gap between cancer drug discovery and early development. It will take potential cancer drugs, primarily discovered by Cancer Research UK, from discovery through to entry to Phase II clinical trials before partnering with pharmaceutical and biotechnology companies. Sixth Element Capital was appointed to manage the fund.
Sixth Element On Bridging The Divide To Get Drugs To Patients Faster
A fund to bridge the UK financing gap between cancer drug discovery and early treatment development is managed by Sixth Element Capital and making an innovative impact.
More from Clinical Trials
• By
The Italian drugmaker gets rights to Phase III-ready asset radiprodil.
• By
New CEO Renée Aguiar-Lucander is marking her mark.
• By
Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.
• By
Several drug makers are working to bring new advances to small-cell lung cancer, a fast-growing cancer with limited treatment options.
More from R&D
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
• By
The UK major's asthma drug gets a key expanded approval.
• By
Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.